Dementia Matters

How can we ensure that all communities are represented in Alzheimer’s and related dementias research and have access to the latest treatments and interventions? Dr. Carl Hill, the chief diversity, equity and inclusion (DEI) officer for the Alzheimer's Association, joins the podcast to delve into the significance of representation, diversity, equity, equality and inclusion within Alzheimer's disease research. He discusses the challenges of underrepresentation in clinical trials, the importance of community-based participatory research (CBPR) and the social determinants of health that influence Alzheimer's risk. Guest: Carl V. Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer's Association Show Notes Learn more about the Alzheimer’s Association’s effort in DEI from their inaugural DEI report. Learn more about race-related topics in Alzheimer’s disease from the Alzheimer’s Association International Conference (AAIC) 2022 here, including a study on the impact of racism on the brain and find

Many people living with dementia experience behavioral symptoms alongside changes in their cognition. What can care partners and healthcare providers do to manage these behavioral changes? After leading the Wisconsin Alzheimer’s Disease Research Center’s (ADRC) annual Dr. Daniel I. Kaufer Lecture, Dr. Helen Kales joins the podcast to discuss agitation and other behavioral symptoms of dementia, the use of medications to manage these symptoms, and different caregiving approaches for addressing these behavioral changes in people living with dementia. Guest: Helen Kales, MD, geriatric psychiatrist, Joe P. Tupin Endowed Professor of Psychiatry, Chair, Department of Psychiatry and Behavioral Sciences, University of California, Davis   Show Notes Watch the recording of Dr. Kales’ lecture, "Agitation is not a disease: How can we better manage the behavioral and psychological symptoms of dementia?,” on YouTube. Learn more about the DICE approach, discussed at 21:01, on The DICE Approach website. Learn more about the a

Gina Green-Harris joins the podcast to discuss the importance of collaborating with communities in Alzheimer’s research. Sharing her experience as a researcher with the Wisconsin Alzheimer’s Institute (WAI) and the All of Us research program, she describes the key tenets of community engagement and explains ways researchers can build intentional, sustainable partnerships with communities throughout the research process This episode is part of a series featuring speakers from the National Alzheimer’s Coordinating Center’s (NACC) Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations. Guest: Gina Green-Harris, MBA, director, Wisconsin Alzheimer’s Institute Regional Milwaukee Office, co-primary investigator, co-director, University of Wisconsin–Madison’s All of Us research program Show Notes Learn more about Gina Green-Harris on the Wisconsin Alzheimer’s Institute’s website and on the UW Institute for Clinical and Translational Research’s we

The APOE gene is recognized as a significant genetic risk factor for cognitive decline, with different alleles, like APOE e2, being seen as protective against decline and others, like APOE e4, indicating an increased risk for cognitive decline. However, new studies are looking at whether these trends are universal across different racial and ethnic groups. Dr. Cally Xiao joins the podcast to discuss her study, which focuses on how different APOE alleles affect risk for Alzheimer’s disease within Hispanic populations compared to non-Hispanic populations. Guest: Cally Xiao, PhD, Project Specialist, Global Alzheimer’s Association Interactive Network, Laboratory of Neuro Imaging, University of Southern California Show Notes Follow Dr. Xiao on Twitter.  Learn more about GAAIN on their website or on Twitter.  Read more about the study, “Comparison of genetic and health risk factors for mild cognitive impairment and Alzheimer's disease between Hispanic and non-Hispanic white participants,” online through the journal

On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Pryzbelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system. Guest: Robert Pryzbelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health Show Notes Read more about Lecanemab’s Appropriate Use Guidelines on our website. Read the FDA’s press release, “FDA Converts Novel Alzheimer’s Disease

Dr. Crystal Glover, health equity in aging researcher at Rush Alzheimer’s Disease Center, joins the podcast to discuss the importance of increasing brain donations and tissue samples from older adults of underrepresented backgrounds. Dr. Glover talks about the reasons why participants may be interested in brain donations, the barriers that they may face, and the benefits of combining both qualitative and quantitative data within her research. This episode is part of a series featuring speakers from the National Alzheimer’s Coordinating Center’s (NACC) Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations.  Guest: Crystal Glover, PhD, leader, Outreach, Recruitment, and Engagement Core, Rush Alzheimer’s Disease Center, Associate Professor, Department of Psychiatry and Behavioral Sciences, Division of Behavioral Sciences, Rush Medical College Show Notes Follow Dr. Glover on Twitter.  Learn more about Dr. Glover on Rush University’s website.

On June 9, 2023, the Food and Drug Administration’s (FDA) advisory committee unanimously voted to approve lecanemab, moving the treatment one step closer to full FDA approval. In the lead up to the FDA’s official announcement expected in early July, Dr. Paul Aisen joins the podcast to discuss Alzheimer’s disease clinical trials. Aisen,  the founding director of the Alzheimer’s Therapeutic Research Institute (ATRI) and a leading figure in Alzheimer’s disease research for over three decades, talks about the Phase 3 clinical trials for lecanemab and gantenerumab and shares highlights from the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference. Guest: Paul Aisen, MD, professor of neurology, Keck School of Medicine, University of Southern California, Director, Alzheimer’s Therapeutic Research Institute  Show Notes Find out more about Dr. Aisen on Keck School of Medicine’s website. Follow the Alzheimer’s Therapeutic Research Institute on Facebook andTwitter. Listen to the episode with Dr. Roderick Corriv

Dr. Lisa Barnes joins the podcast to discuss her research focusing on how social determinants of health, specifically racial differences, affect chronic diseases of aging.She explains the difference between equality, equity and justice, and the different drivers of disparities within the medical field. This episode is part of a series featuring speakers from the National Alzheimer’s Coordinating Center’s (NACC) Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations.  Guest: Lisa Barnes, PhD, Alla V. and Solomon Jesmer Professor of Gerontology and Geriatric Medicine, Rush University Medical Center, neuropsychologist, Rush Alzheimer’s Disease Research Center Show Notes Learn more information about the NACC and watch the presentation recordings from the Spring 2023 ADRC Meeting on their website. Watch Dr. Barnes’ presentation at the Fall 2022 ADRC Meeting, “Social Determinants of Health and Health Equity.” Read more about the study Dr. Barne

To mark National Mediterranean Diet Month, Dr. Nathaniel Chin discusses a recent National Institute on Aging-funded study that suggests the MIND and Mediterranean diets — both rich in vegetables, fruits, whole grains, olive oil, beans and fish — are associated with fewer signs of Alzheimer’s disease in the brains of older adults. In this special episode of Dementia Matters, Chin also revisits his interview with the creator of the MIND diet, Dr. Martha Clare Morris, shares recommendations for ten things to incorporate into your diet and five things to limit, and touches on the benefits of intermittent fasting. Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on May 16, 2023. Watch the recording. Learn more about National Mediterranean Diet Month on our website. Read the National Institute on Aging’s press release, “MIND and Mediterranean diets linked to fewer signs of Alzheimer’s brain pathology,” published May 4, 2023. Listen to Dr. Martha Clare Morris’s ep

Dr. Sarah Biber, the program director for the National Alzheimer’s Coordinating Center (NACC), joins the podcast to discuss efforts to increase representation and equitable practices across the 37 Alzheimer’s Disease Research Centers (ADRCs). She discusses key disparities in Alzheimer’s disease research, why diversity and inclusion are imperative in research, and what is being done to address these disparities with the data collected from research participants. This episode is the first of an upcoming series featuring speakers from the Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations.    Guest: Sarah Biber, PhD, program director, National Alzheimer’s Coordinating Center Show Notes Learn more information about the National Alzheimer’s Coordinating Center and watch the presentation recordings from the Spring ADRC Meeting on their website Watch Dr. Biber’s presentation at the Fall ADRC Meeting, “Delivering on NACC’s Mission Through Mod

Recorded live from the Wisconsin ADRC’s Alzheimer’s Disease & Related Dementias Research Day, Dr. Nathaniel Chin discusses the importance of mentorship and the future of neuroscience and Alzheimer’s disease research with the Alzheimer’s Association International Conference® (AAIC) Neuroscience Next 'One to Watch' award recipients and the event’s organizers. Guests: Barbara Bendlin, PhD, director, UW-Madison Neuroscience and Public Policy Program, leader, Research Education Component (REC), Wisconsin Alzheimer’s Disease Research Center; Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer’s Association; Nadia Dehghani, BS, co-chair, Neuroscience Next Scientific Program Committee; Claire André, PhD, postdoctoral fellow, Center for Advanced Research in Sleep Medicine, Université de Montréal; Chinmayi Balusu, founder, CEO, Simply Neuroscience; Kacie Deters, PhD, assistant professor, University of California Los Angeles; Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Pu

Dr. Natascha Merten joins the podcast to discuss her study focused on trends in cognitive function across generations. Merten also explains her research on the associations between sensory and motor functions and blood-based biomarkers for neurodegeneration and dementia. Guest: Natascha Merten, PhD, MS, director, Beaver Dam Offspring Study-Neurocognitive Aging Study, assistant professor, Departments of Population Health Sciences and Medicine, University of Wisconsin–Madison Show Notes Read Dr. Merten’s studies, “Better cognitive function in younger generations - Insights from two cohort studies of middle-aged to older adults in Wisconsin,” and “Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife,” through ScienceDirect. Read Dr. Merten’s abstract from the 2022 Alzheimer’s Association’s International Conference through the journal Alzheimer’s & Dementia. Read about Dr. Merten’s R01 grant, “Dr. Natascha Merten Awarded NIA Funding To

Dr. Annalise Rahman-Filipiak joins the podcast to discuss her research focused on disclosing neuroimaging biomarkers across diverse populations. She addresses why some people might want to know their biomarker results, while others might not, and how careful disclosure of these results to at-risk individuals may help prepare them and their families for the future through personalized treatment, research engagement, advanced planning and emotional support. Guest: Annalise Rahman-Filipiak, PhD, assistant professor, neuropsychologist, department of psychiatry, University of Michigan Show Notes Learn more about Dr. Rahman-Filipiak on the University of Michigan’s website. Read Dr. Rahman-Filipiak’s article, “Interest in and perceived benefits and risks of Alzheimer’s disease clinical and biomarker results disclosure among diverse participants and care partners,” at the journal Alzheimer’s & Dementia website. Follow Dr. Rahman-Filipiak on Twitter @RahFlipPhD. Connect with us Find transcripts and more at our web

For families and dementia care partners, palliative care can help improve the quality of life for their loved ones and themselves by addressing physical and emotional needs. However, starting conversations around end-of-life care and planning can be difficult. Dr. Elizabeth Bukowy joins the podcast to explain the difference between palliative and hospice care, share how families and care partners can start these challenging conversations, and discuss why these discussions are essential for quality of life. Guest: Elizabeth Bukowy, DO, CMD, assistant professor, Medical College of Wisconsin Division of Geriatrics; medical director, Lutheran Home and Congregational Home Show Notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Watch the pre-conference workshop for new dementia care professionals on our YouTube channel. Dr. Bukowy’s keynote starts at 1:46:46 in the r

When seeking medical information and treatment, different racial and ethnic groups may require specially tailored information to relate to, understand and apply to their own experiences. In this episode, Dr. Fayron Epps joins the podcast to talk about the unique experiences of African American caregivers and her lab's work to provide education and assistance to their needs. Epps seeks to promote quality of life for families affected by dementia through research, education and service. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Research and Related Dementias. Guest: Fayron Epps, PhD, RN, FGSA, FAAN, assistant professor, Nell Hodgson Woodruff School of Nursing, Emory University, principal investigator, Faith Village Research Lab, founder, Alter Show Notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full ke

Mild cognitive impairment (MCI) is an emerging term in the field of Alzheimer’s disease and related dementias, characterized as the stage between the expected decline in memory and thinking that happens with age and the more severe decline of dementia. In this episode, Dr. Ronald Petersen joins the podcast to talk about how MCI compares to dementia, its many causes, and the impact of new lifestyle and drug interventions on its progression, as well as how his career led him to study Alzheimer's disease and MCI. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Disease and Related Dementias. Guest: Ronald C. Petersen, MD, PhD, director, Mayo Clinic Alzheimer's Disease Research Center, director, Mayo Clinic Study of Aging, Cora Kanow Professor of Alzheimer’s Disease Research, Mayo Clinic College of Medicine Show notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisc

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023. Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on February 13, 2023. Watch the video interview with Drs. Carlsson and Johnson here. In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen. Read more about the AHEAD study and A4 study at their respective websites. Connect with us Find transcripts and more a

Former Governor of Wisconsin, Martin Schreiber, returns to Dementia Matters to discuss different methods for communicating with a loved one with Alzheimer’s disease, including therapeutic fibbing. Governor Schreiber has been a widely outspoken advocate for Alzheimer’s disease while caring for his late wife Elaine, who passed away from the disease in April of 2022. In this episode, he also talks about his book, My Two Elaines, where he opens up about his experience as a caregiver. Guest: Martin Schreiber, Former Governor of Wisconsin (1977-1979), Former Lt. Governor of Wisconsin (1971-1977) Show Notes Learn more about Martin Schreiber and his book, My Two Elaines, at his website, or follow him on Facebook. Listen to Governor Schreiber’s previous appearance on our website or wherever you get your podcasts.  Connect with us Find transcripts and more at our website. Email Dementia Matters Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives. Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council Show Notes Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website. Learn more about Part the Cloud at their website. Learn more about the Alzheimer's Association at their website. Learn more about Dr. Pike in her

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Show Notes In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release. Read the FDA’s news release regarding lecanemab’s accelerated approval on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.